Health & Medicine | Apr 20, 2026 | 8 min read | By Bryan White

Can We Sniff Away Brain Fog? The New Science of Reversing Cognitive Decline

Biology * Public Health * Neuroscience

Introduction: Neuroinflammaging and Reversible Cognitive Decline

The mammalian central nervous system depends on oxidative phosphorylation to sustain synaptic transmission and cellular homeostasis. While age-related declines in spatial memory and associative recognition ("brain fog") were long considered irreversible neuronal attrition, contemporary neurobiology identifies "neuroinflammaging" -- a chronic, sterile inflammatory feedback loop in the hippocampus driven by hyperactivated microglia and reactive astrocytes -- as a primary catalyst of synaptic failure and Alzheimer's disease.[1][2][4] In early 2026, Texas A&M University researchers led by Dr. Leelavathi N. Madhu, Dr. Maheedhar Kodali, and Dr. Ashok K. Shetty reported in the Journal of Extracellular Vesicles (DOI: 10.1002/jev2.70232) that intranasal administration of extracellular vesicles from human induced pluripotent stem cell-derived neural stem cells (hiPSC-NSC-EVs) suppresses neuroinflammation, restores mitochondrial function, and rescues cognition in aged mice via epigenetic microRNA cargo.[1][2]

The Molecular Pathophysiology of Neuroinflammaging

Across the lifespan, reactive oxygen species degrade mitochondrial membranes, leaking mitochondrial DNA (mtDNA) from damaged mitochondria into the cytoplasm as a viral-like damage-associated molecular pattern (DAMP).[2][3][7][8] Cytosolic mtDNA binds cyclic GMP-AMP synthase (cGAS) to generate cGAMP, activating STING on the endoplasmic reticulum.[9] STING phosphorylates TBK1 and IRF3 to drive Type 1 interferon (IFN-1) and NF-kappaB transcription, promoting astrogliosis and neuronal apoptosis.[9][10][11][13] Simultaneously, oxidative stress and misfolded proteins trigger the microglial NLRP3 inflammasome and ASC adaptor to activate Caspase-1, cleaving IL-1 beta and IL-18 to impair synaptic plasticity.[2][6]

| Inflammatory Pathway | | Primary Trigger / DAMP | | Key Mediators | | Pathological Outcomes |

| cGAS-STING Axis | | Cytosolic mtDNA leakage | | cGAS, cGAMP, STING, TBK1, IRF3 | | Type 1 interferon transcription; microglial activation; NF-kappaB induction. |

| NLRP3 Inflammasome | | ROS, ATP, misfolded proteins | | NLRP3, ASC, Caspase-1 | | Maturation and secretion of IL-1 beta and IL-18 cytokines. |

| JAK-STAT Signaling | | Secreted interferons/interleukins | | JAK, STAT factors | | Amplification of ISGs; stabilization of neurotoxic microglia. |

| p38/MAPK Signaling | | Oxidative stress, cytokines | | Myd88, Ras, pMAPK, AP-1 | | Chronic neuroinflammation; accelerated senescence and apoptosis. |

Intranasal Extracellular Vesicle Pharmacokinetics

Unlike small molecules, monoclonal antibodies, or surgical cell grafts limited by the blood-brain barrier (BBB) and immunogenicity, passage-11 hiPSC-NSCs secrete nanoscale lipid bilayer vesicles carrying regulatory proteins, lipids, messenger RNA, and microRNAs.[2][15][17][19] Isolated via anion-exchange and size-exclusion chromatography (CD9+, CD63+, CD81+, ALIX+, TSG101+, GM130-), intranasally delivered PKH-26-labeled EVs (4 billion particles) bypassed the BBB via olfactory and trigeminal pathways to permeate the brain within 6 hours, selectively targeting IBA-1+ microglia, neurons, and GFAP+ astrocytes.[2][12][15][18][20][21]

| Delivery Route | | Brain Access Mechanism | | Pharmacological Advantages | | Clinical Limitations |

| Intravenous | | Must cross the Blood-Brain Barrier | | Standard clinical administration | | Poor brain penetrance; hepatic/splenic clearance. |

| Intracerebroventricular | | Direct surgical CSF injection | | Maximum local bioavailability | | Highly invasive; infection and hemorrhage risk. |

| Intranasal Delivery | | Olfactory and trigeminal nerve tracts | | Non-invasive; bypasses BBB; rapid CNS uptake | | Mucociliary clearance; human dose-scaling requirements. |

Epigenetic MicroRNA Reprogramming of cGAS-STING and NLRP3

Through post-transcriptional RNA interference, hiPSC-NSC-EVs silence inflammatory cascades simultaneously:[1][2][22] miR-181a-5p degrades STING mRNA (validated in cGAMP-stimulated RAW-Lucia-ISG macrophages, where miR-181a-5p depletion abolished STING inhibition); miR-30e-3p silences NLRP3 mRNA to block Caspase-1 and IL-1 beta release (validated in nigericin-stimulated RAW-ASC macrophages); miR-21-5p inhibits NF-kappaB while boosting IL-10; miR-103a suppresses COX-2; and Pentraxin-3 (PTX3) shifts microglia to a neuroprotective state.[2][5][14][23]

| Cargo Component | | Classification | | Validated Target | | Mechanism and Outcome |

| miR-181a-5p | | microRNA | | STING mRNA | | Suppresses cGAS-STING and IFN-1 signaling triggered by cytosolic mtDNA. |

| miR-30e-3p | | microRNA | | NLRP3 mRNA | | Blocks NLRP3 assembly, Caspase-1 activation, and IL-1 beta/IL-18 release. |

| miR-21-5p | | microRNA | | NF-kappaB / TNF-alpha | | Restrains pro-inflammatory signaling and elevates IL-10 synthesis. |

| miR-103a | | microRNA | | COX-2 | | Reduces prostaglandin synthesis and ambient oxidative stress. |

| Pentraxin-3 (PTX3) | | Protein | | Microglial Receptors | | Polarizes microglia toward neuroprotection and supports BBB integrity. |

Single-Cell Transcriptomics, Histological Healing, and Cognitive Rescue

Across 125 C57BL6/J mice (59 males, 66 females), administering two intranasal doses of 12 billion hiPSC-NSC-EVs one week apart at 18 months of age reversed Disease-Associated Microglia (DAM) signatures by 20.5 months.[2][16] Hippocampal single-cell RNA sequencing and GeneWalk analysis confirmed downregulation of NLRP3, cGAS-STING, JAK-STAT, and p38/MAPK alongside upregulated mitochondrial oxidative phosphorylation genes, reduced IBA-1+ clustering, decreased GFAP+ astrogliosis ($p < 0.0001$), and elevated Nrf2 and superoxide dismutase (SOD).[2][5]

| Biomarker / Pathway | | Localization | | Observed Effect Post-EV Therapy |

| NLRP3, ASC, Caspase-1 | | Microglia | | Downregulated transcription and blocked inflammasome assembly. |

| IL-1 beta & IL-18 | | Parenchyma | | Significant reduction in secreted pro-inflammatory cytokines. |

| p-STING & IRF3 | | Microglia / Neurons | | Suppressed chronic Type-1 Interferon (IFN-1) response. |

| IBA-1 & GFAP | | Microglia / Astrocytes | | Reduced microglial clustering and astrocyte hypertrophy ($p < 0.0001$). |

| Nrf2 & SOD | | Intracellular | | Upregulated antioxidant capacity and mitochondrial integrity. |

On Novel Object Recognition (NORT) and Object Location (OLT) behavioral tests, 20.5-month-old treated mice recovered youthful Discrimination Index scores across both sexes, while ancillary 5xFAD Alzheimer's experiments showed reduced amyloid-beta plaques and phosphorylated tau.[1][2][5][16]

Conclusion: Clinical Translation of Neural Stem Cell Vesicles

Backed by a U.S. patent filing, intranasal hiPSC-NSC-EVs demonstrate that age-related cognitive decline is reversible by targeting cGAS-STING and NLRP3 via miR-181a-5p and miR-30e-3p, pending GMP biomanufacturing scale-up and human nasal pharmacokinetic trials.[1][5][15][18][24]

Updates... (Nov 21, 2026): Clarified that cytosolic mitochondrial DNA (mtDNA) leaks from damaged mitochondria rather than the nucleus; replaced a secondary summary link with the primary Nature study on microglial cGAS-STING signaling (Gulen et al., Aug 2023); standardized publication dates across all 24 references; corrected author, volume, page, and publication-year metadata against CrossRef and institutional records (including Madhu et al. Feb 2026, Yan et al. Feb 2026, Ayyubova et al. Dec 2023, and Open Exploration Jan 2026); and harmonized reference list formatting.

References & Primary Sources

* [1] Texas A&M Stories (Apr 14, 2026). Scientists reverse brain aging, with a nasal spray. -- https://stories.tamu.edu/news/2026/04/14/scientists-reverse-brain-aging-with-a-nasal-spray/

* [2] Madhu, L. N., Kodali, M., Rao, S., Attaluri, S., Upadhya, R., Shankar, G., et

al. (Feb 8, 2026). Intranasal Human NSC Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS STING Signalling, in Aged Hippocampus. Journal of Extracellular Vesicles, 15(2), e70232. -- https://doi.org/10.1002/jev2.70232

* [3] Lifespan Research Institute (May 10, 2025). Chronic Inflammation. -- https://lifespan.io/topic/why-we-age-chronic-inflammation/

* [4] Yan, R., Feng, H., & Zhang, J. (Feb 12, 2026). Immunosenescence and inflammaging in Parkinson's disease: mechanisms and therapeutic prospects. Frontiers in Immunology, 17, 1749278. -- https://doi.org/10.3389/fimmu.2026.1749278

* [5] Neuroscience News (Apr 14, 2026). Nasal Spray Reverses Brain Aging and Inflammation. -- https://neurosciencenews.com/nasal-spray-reverse-brain-aging-30519/

* [6] Kaur, B., Biby, S., Namme, J. N., More, S., Xu, Y., & Zhang, S. (2025). Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors. Advances in Pharmacology, 103-157. -- https://doi.org/10.1016/bs.apha.2024.10.004

* [7] Zhang, G., Wei, H., Zhao, A., Yan, X., Zhang, X., & Gan, J. (Feb 7, 2025). Mitochondrial DNA leakage: underlying mechanisms and therapeutic implications in neurological disorders. Journal of Neuroinflammation, 22(1), 34. -- https://doi.org/10.1186/s12974-025-03363-0

* [8] Gulen, M. F., Samson, N., Keller, A., Schwabenland, M., Liu, C., Gl ck, S., et al. (Aug 2, 2023; print Aug 10, 2023). cGAS-STING drives ageing-related inflammation and neurodegeneration. Nature, 620(7973), 374-380. -- https://doi.org/10.1038/s41586-023-06373-1

* [9] Li, H., Cai, R., Zhou, Y., Jiang, Y., & Tan, S. (Oct 15, 2025). cGAS-STING signaling in brain aging and neurodegeneration: molecular links and therapeutic perspectives. Journal of Neuroinflammation, 22(1), 235. -- https://doi.org/10.1186/s12974-025-03563-8

* [10] Zhang, S., Zheng, R., Pan, Y., & Sun, H. (Mar 31, 2023). Potential Therapeutic Value of the STING Inhibitors. Molecules, 28(7), 3127. -- https://doi.org/10.3390/molecules28073127

* [11] Xiao, Y., Ma, Y., Zhao, J., Zhang, X., Gan, C., & Gao, J. (Nov 21, 2025; print Dec 20, 2025). cGAS-STING signaling pathway as a therapeutic target in human diseases. Chinese Medical Journal, 138(24), 3251-3284. -- https://doi.org/10.1097/cm9.0000000000003904

* [12] Li, P., Sun, S., Zhu, X., Liu, X., Yin, R., & Chen, Y. (Mar 21, 2025). Intranasal delivery of engineered extracellular vesicles promotes neurofunctional recovery in traumatic brain injury. Journal of Nanobiotechnology, 23(1), 229. -- https://doi.org/10.1186/s12951-025-03181-9

* [13] Alzheimer's Drug Discovery Foundation (Jan 11, 2023). cGAS-STING Inhibitors (Cognitive Vitality Report). -- https://www.alzdiscovery.org/uploads/cognitive_vitality_media/cGAS-STING.pdf

* [14] Li, D., Yang, H., Ma, J., Luo, S., Chen, S., & Gu, Q. (Dec 22, 2017; print Apr 2018). MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's

disease by targeting Nlrp3. Human Cell, 31(2), 106-115. -- https://doi.org/10.1007/s13577-017-0187-5

* [15] Upadhya, R., Madhu, L. N., Attaluri, S., Gita , D. L. G., Pinson, M. R., & Kodali, M. (Aug 26, 2020; print Sep 2020). Extracellular vesicles from human iPSC-derived neural stem cells: miRNA and protein signatures, and anti-inflammatory and neurogenic properties. Journal of Extracellular Vesicles, 9(1), 1809064. -- https://doi.org/10.1080/20013078.2020.1809064

* [16] Madhu, L. N., Kodali, M., Upadhya, R., Rao, S., Somayaji, Y., & Attaluri, S. (Nov 5, 2024). Extracellular vesicles from human-induced pluripotent stem cell-derived neural stem cells alleviate proinflammatory cascades within disease-associated microglia in Alzheimer's disease. Journal of Extracellular Vesicles, 13(11), e12519. -- https://doi.org/10.1002/jev2.12519

* [17] Gotoh, S., Kawabori, M., & Fujimura, M. (Sep 22, 2023; print Jun 2024). Intranasal administration of stem cell-derived exosomes for central nervous system diseases. Neural Regeneration Research, 19(6), 1249-1255. -- https://doi.org/10.4103/1673-5374.385875

* [18] Ayyubova, G., Kodali, M., Upadhya, R., Madhu, L. N., Attaluri, S., & Somayaji, Y. (Dec 12, 2023). Extracellular vesicles from hiPSC-NSCs can prevent peripheral inflammation-induced cognitive dysfunction with inflammasome inhibition and improved neurogenesis in the hippocampus. Journal of Neuroinflammation, 20(1), 297. -- https://doi.org/10.1186/s12974-023-02971-y

* [19] Wang, K., Kumar, U. S., Sadeghipour, N., Massoud, T. F., & Paulmurugan, R. (Nov 1, 2021; print Nov 23, 2021). A Microfluidics-Based Scalable Approach to Generate Extracellular Vesicles with Enhanced Therapeutic MicroRNA Loading for Intranasal Delivery to Mouse Glioblastomas. ACS Nano, 15(11), 18327-18346. -- https://doi.org/10.1021/acsnano.1c07587

* [20] Kou, D., Gao, Y., Li, C., Zhou, D., Lu, K., & Wang, N. (Mar 30, 2023; print Jun 14, 2023). Intranasal Pathway for Nanoparticles to Enter the Central Nervous System. Nano Letters, 23(11), 5381-5390. -- https://doi.org/10.1021/acs.nanolett.2c05056

* [21] Wu, X., Zang, R., Qiu, Y., Zhang, Y., Peng, J., & Cheng, Z. (Jun 13, 2025). Intranasal Drug Delivery Technology in the Treatment of Central Nervous System Diseases: Challenges, Advances, and Future Research Directions. Pharmaceutics, 17(6), 775. -- https://doi.org/10.3390/pharmaceutics17060775

* [22] Ma, Y.-M., & Zhao, L. (Nov 23, 2023). Mechanism and Therapeutic Prospect of miRNAs in Neurodegenerative Diseases. Behavioural Neurology, 2023, 1-24. -- https://doi.org/10.1155/2023/8537296

* [23] Upadhya, R., Madhu, L. N., Rao, S., & Shetty, A. K. (May 17, 2022). Proficiency of Extracellular Vesicles From hiPSC-Derived Neural Stem Cells in Modulating Proinflammatory Human Microglia: Role of Pentraxin-3 and miRNA-21-5p. Frontiers in Molecular Neuroscience, 15, 845542. -- https://doi.org/10.3389/fnmol.2022.845542

* [24] Open Exploration (Jan 27, 2026). Stem cell-derived exosomes as neurotherapeutic agents: mechanisms of immunomodulation and neural regeneration in

neurodegenerative disorders. --
https://www.explorationpub.com/Journals/ent/Article/1004137